Invasive pituitary adenomas: significance of proliferation parameters
- PMID: 11081161
- DOI: 10.1023/a:1009931413106
Invasive pituitary adenomas: significance of proliferation parameters
Abstract
Although most pituitary adenomas behave in a purely benign fashion, microscopic invasion of the subjacent dura is very common, and clinically overt infiltration of the surrounding dura and bone is apparent at intraoperative inspection in about one third of cases. The factors governing invasive behavior remain unknown but are believed to be separate from those regulating cell proliferation. Histological features alone do not distinguish between benign, invasive, and malignant tumors of adenohypophyseal origin. Multiple attempts have been made to identify prognostic markers of aggressive behavior among these tumors. They include cytogenetic analysis of putative tumor suppressor genes or proto-oncogenes as well as immunohistochemical detection of cell-cycle specific antigens. At present, however, these analyses can neither distinguish the indolent pituitary adenoma from one that will pursue an invasive course, nor reliably predict the prognosis in individual patients.
Similar articles
-
Pituitary tumors: prognostic indicators.Endocrine. 2005 Oct;28(1):57-66. doi: 10.1385/ENDO:28:1:057. Endocrine. 2005. PMID: 16311411 Review.
-
p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions.Neurosurgery. 1996 Apr;38(4):765-70; discussion 770-1. Neurosurgery. 1996. PMID: 8692397
-
The long-term significance of microscopic dural invasion in 354 patients with pituitary adenomas treated with transsphenoidal surgery.J Neurosurg. 2002 Feb;96(2):195-208. doi: 10.3171/jns.2002.96.2.0195. J Neurosurg. 2002. PMID: 11838791
-
Clinical Implications of Accurate Subtyping of Pituitary Adenomas: Perspectives from the Treating Physician.Turk Patoloji Derg. 2015;31 Suppl 1:4-17. doi: 10.5146/tjpath.2015.01311. Turk Patoloji Derg. 2015. PMID: 26177314 Review.
-
Proliferation parameters for pituitary adenomas.Acta Neurochir Suppl. 1996;65:18-21. doi: 10.1007/978-3-7091-9450-8_7. Acta Neurochir Suppl. 1996. PMID: 8738487 Review.
Cited by
-
MicroRNA involvement in a metastatic non-functioning pituitary carcinoma.Pituitary. 2015 Oct;18(5):710-21. doi: 10.1007/s11102-015-0648-3. Pituitary. 2015. PMID: 25862551
-
Management of aggressive pituitary adenomas and pituitary carcinomas.J Neurooncol. 2014 May;117(3):459-68. doi: 10.1007/s11060-014-1413-6. Epub 2014 Mar 2. J Neurooncol. 2014. PMID: 24584748 Review.
-
Genomics and Epigenomics of Pituitary Tumors: What Do Pathologists Need to Know?Endocr Pathol. 2021 Mar;32(1):3-16. doi: 10.1007/s12022-021-09663-4. Epub 2021 Jan 12. Endocr Pathol. 2021. PMID: 33433883 Review.
-
Malignant transformation in non-functioning pituitary adenomas (pituitary carcinoma).Pituitary. 2018 Apr;21(2):217-229. doi: 10.1007/s11102-017-0857-z. Pituitary. 2018. PMID: 29299820 Review.
-
How to Classify the Pituitary Neuroendocrine Tumors (PitNET)s in 2020.Cancers (Basel). 2020 Feb 22;12(2):514. doi: 10.3390/cancers12020514. Cancers (Basel). 2020. PMID: 32098443 Free PMC article. Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical